The 5 bullish ratings from analysts indicate a positive outlook for EyePoint Pharmaceuticals. The average price target of $31.2, despite being a 4.5% decrease from the previous target, still implies significant upside potential compared to the current price of $6.45. This suggests that the stock price is likely to go up in the short term.